TEMSIROLIMUS ACCORD 30mg concentrate+solvent for solution for infusion medication leaflet

L01EG01 • temsirolimus • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mammalian target of rapamycin (MTOR) kinase inhibitors

Temsirolimus is an mTOR (mammalian target of rapamycin) inhibitor used for the treatment of advanced renal cancer and other types of tumors. It works by inhibiting the growth and proliferation of tumor cells, thereby reducing disease progression.

The medication is administered via intravenous infusion, usually once a week, as directed by a doctor. It is important for patients to be closely monitored during treatment to prevent potential complications.

Patients should be aware of potential side effects, such as skin rashes, fatigue, or elevated blood glucose levels. It is important to inform the doctor of any unusual symptoms.

Common side effects include skin rashes, fatigue, nausea, and increased cholesterol or glucose levels. In rare cases, severe reactions such as serious infections or kidney failure may occur. Patients should be informed of these risks before starting treatment.